Avid Bioservices Inc (CDMO)

[2ndstr2thert]

Do we still own the rights to VEA tech ?


TECHNICLONE ISSUED PATENT ON VASOPERMEATION ENHANCEMENT.
Feb, 2000
Biotech Business
Techniclone Corporation (NASDAQ:TCLN), Tustin, Calif., has announced that the U.S. Patent Office has granted a US Patent No. 6007817 for Techniclone's Vasopermeation Enhancement Agent ("VEA") technology. The VEA technology is one of Techniclone's platform technologies, which will be used to enhance drug uptake in solid tumors. This broad patent covers the use of the VEA agents for the treatment of all solid tumors in conjunction with chemotherapeutic agents, monoclonal antibodies, cytokines and other therapeutic agents.

The technology was developed to be administered prior to the administration of most existing cancer therapies. Preclinical studies in animal models have shown that drug uptake can be increased up to 400% in specific instances by using the VEA technology as a pretreatment.
http://www.entrepreneur.com/tradejournals/article/58674378.html